The activation of α1-adrenoceptors is implicated in the antidepressant-like effect of creatine in the tail suspension test  by Cunha, Mauricio P. et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry 44 (2013) 39–50
Contents lists available at SciVerse ScienceDirect
Progress in Neuro-Psychopharmacology & Biological
Psychiatry
j ourna l homepage: www.e lsev ie r .com/ locate /pnpThe activation of α1-adrenoceptors is implicated in the antidepressant-like effect of
creatine in the tail suspension test
Mauricio P. Cunha, Francis L. Pazini, Ágatha Oliveira, Luis E.B. Bettio, Julia M. Rosa,
Daniele G. Machado, Ana Lúcia S. Rodrigues ⁎
Department of Biochemistry, Center of Biological Sciences, Universidade Federal de Santa Catarina, 88040-900, Florianópolis, SC, BrazilAbbreviations: AMPT, α-methyl-p-tyrosine; ANOVA
dimethylsulfoxide; FST, forced swimming test; TST, tail
⁎ Corresponding author. Tel.: +55 48 3721 5043; fax
E-mail addresses: analucia@mbox1.ufsc.br, alsrodri@
0278-5846 © 2013 Elsevier Inc.
http://dx.doi.org/10.1016/j.pnpbp.2013.01.014
Open access under the Elsea b s t r a c ta r t i c l e i n f oArticle history:
Received 5 September 2012
Received in revised form 8 January 2013
Accepted 18 January 2013
Available online 26 January 2013
Keywords:
Antidepressant
Creatine
Noradrenaline
Tail suspension testThe antidepressant-like activity of creatine in the tail suspension test (TST) was demonstrated previously by
our group. In this study we investigated the involvement of the noradrenergic system in the
antidepressant-like effect of creatine in the mouse TST. In the ﬁrst set of experiments, creatine administered
by i.c.v. route (1 μg/site) decreased the immobility time in the TST, suggesting the central effect of this com-
pound. The anti-immobility effect of peripheral administration of creatine (1 mg/kg, p.o.) was prevented by
the pretreatment of mice with α-methyl-p-tyrosine (100 mg/kg, i.p., inhibitor of tyrosine hydroxylase),
prazosin (1 mg/kg, i.p., α1-adrenoceptor antagonist), but not by yohimbine (1 mg/kg, i.p., α2-adrenoceptor
antagonist). Creatine (0.01 mg/kg, subeffective dose) in combination with subeffective doses of amitriptyline
(1 mg/kg, p.o., tricyclic antidepressant), imipramine (0.1 mg/kg, p.o., tricyclic antidepressant), reboxetine
(2 mg/kg, p.o., selective noradrenaline reuptake inhibitor) or phenylephrine (0.4 μg/site, i.c.v., α1-
adrenoceptor agonist) reduced the immobility time in the TST as compared with either drug alone. These
results indicate that the antidepressant-like effect of creatine is likely mediated by an activation of α1-
adrenoceptor and that creatine produces synergistic effects in the TST with antidepressants that modulate
noradrenaline transporter, suggesting that an improvement in the response to the antidepressant therapy
may occur when creatine is combined with these antidepressants. Furthermore, the synergistic effect of cre-
atine (0.01 mg/kg, p.o.) and reboxetine (2 mg/kg, p.o.) combination was abolished by the α1-adrenoceptor
antagonist prazosin, indicating that the antidepressant-like effect of combined therapy is likely mediated
by an activation of α1-adrenoceptor.
© 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Depression is one of the most common illnesses characterized by a
broad range of symptoms, including altered mood and cognitive func-
tions, loss of interest or pleasure, feelings of guilt or low self-worth,
disturbed sleep or appetite, low energy and recurrent thoughts of
death or suicide. The antidepressants used for the treatment of this
disorder act by increasing the availability of monoamines (serotonin,
noradrenaline and dopamine) in the synaptic cleft by blocking their
reuptake (tricyclics, selective serotonin reuptake inhibitors, selective
noradrenaline reuptake inhibitors and dopamine reuptake inhibitors)
or its metabolism (monoamine oxidase inhibitors) (Vetulani and
Nalepa, 2000). Requisite brain regions that mediate these events are
unknown, although Samson et al. (2011) reported that activation in
the prefrontal cortex seems to play a crucial role in the treatment
responses of patients with major depression., analysis of variance; DMSO,
suspension test.
: +55 48 3721 9672.
gmail.com (A.L.S. Rodrigues).
vier OA license.Besides the monoaminergic hypothesis, impairment in the brain
energetic metabolism has been implicated in the pathophysiology of de-
pression. Several studies have demonstrated alterations in high-energy
phosphate metabolism in subjects with depression (Kato et al., 1992;
Volz et al., 1998). Indeed, a hypoactive prefrontal cerebral energymetab-
olism has been reported in unipolar and bipolar depression (Forester et
al., 2009; Ketter et al., 2001). Of note, antidepressants treatment in-
creased the energetic metabolism in the brain, since antidepressants
treatment increased the citrate synthase activity in the mitochondrial
brain (Hroudova and Fisar, 2010), creatine kinase activity in the cerebral
cortex (Assis et al., 2009; Réus et al., 2012; Santos et al., 2009; Scaini et al.,
2010) and brain levels of creatine-containing compounds (Papakostas,
2009; Silveri et al., 2003). Furthermore, electroconvulsive shock in-
creased the cerebral glucose utilization in the hippocampus, suggesting
that this intervention that is well-known to cause antidepressant effect,
increases metabolic rates (Orzi et al., 1987). It is, therefore, feasible to
suppose that agents that improve cellular bioenergetics may be useful
in the treatment of depression.
In line with this, creatine (N-aminoiminomethyl-N-methylglycine), a
guanidine compound that plays a pivotal role in brain energy homeostasis
(Andres et al., 2008) and present a signiﬁcant role in the pathophysiology
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Hamilton Depression Rating Scale scores and white matter creatine
levels was shown (Dager et al., 2004). Furthermore, a single prolonged
stress and forced swimming stress was reported to decrease creatine
concentrations in the rat prefrontal cortex (Herring et al., 2008; Kim
et al., 2010; Knox et al., 2010). Noteworthy, creatine supplementation
has been proposed as a putative antidepressant in preclinical studies
(Allen et al., 2010, 2012; Cunha et al., 2012) and clinical trials (Kondo
et al., 2011, 2012; Roitman et al., 2007). However, the mechanisms
underlying its antidepressant effects are not well established. Our
group recently demonstrated that an acute administration of creatine
to mice elicits an antidepressant-like effect in the tail suspension test
(TST) dependent on the dopaminergic activation (Cunha et al., 2012).
Furthermore, considering that noradrenaline terminals regulate extra-
cellular dopamine concentrations in the prefrontal cortex (Yamamoto
and Novotney, 1998), we hypothesized that the antidepressant-like
effect of creatine also involves noradrenergic system modulation.
The noradrenergic system is involved in the regulation ofmany phys-
iological and psychological processes, including themodulation ofmood.
The α-adrenergic receptors modulate noradrenaline release (Rump and
Majewski, 1987), as well as dopamine release (Verheij and Cools, 2009)
and are therefore potential targets for antidepressant drug development.
Of note, a number of antidepressant drugs have been found to increase
α1-adrenoceptors function (Holsboer and Barden, 1996), since they are
able to increase the density of α1-adrenoceptors in the hippocampus
and cerebral cortex of mice and rats (Deupree et al., 2007; Rehavi et
al., 1980) and the α1-adrenoceptor agonist afﬁnity in the cerebral
cortex (Klimek et al., 1991; Nowak and Przegaliński, 1988). Moreover,
the α1-adrenoceptor blockade in the central nervous system induces
depression-related behavior in the TST (Stone and Quartermain, 1999).
Indeed, the α1- and α2-adrenoceptors have been shown to underlie
some of the antidepressant-like responses of drugs in behavioral models
of depression (Danysz et al., 1986; Kitada et al., 1983; Masuda et al.,
2001). Taking into account the established roles of α-adrenoceptors in
mood disorders, we investigate the involvement of the α-adrenoceptor
activation in the antidepressant-like effect of creatine. Furthermore, the
possibility that creatine administration causes an enhancement of the
anti-immobility action of noradrenaline reuptake inhibitors in the TST
was also investigated.
2. Methods
2.1. Animals
Male Swissmice (30–40 g)were obtained from the Central Biothery
of Universidade Federal de Santa Catarina (Santa Catarina, Brazil). Ani-
mals were housed in groups of fourteen animals per plastic cage under
controlled conditions of light (from 07:00 to 19:00 h) and temperature
(21±1 °C) were used. Mice were allowed free access to standard labo-
ratory food and tap water, and to adapt to the laboratory environment
for at least 1 week before the behavioral studies. Each experimental
group consisted of 7–9 animals. Animals were randomly distributed
into speciﬁed experimental groups. All manipulations were carried
out between 14:00–17:00 h, with each animal used only once. All pro-
cedures in this study were performed in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory Animals
and approved by the Ethics Committee of the Institution. All efforts
were made to minimize animals suffering and to reduce the number
of animals used in the experiments.
2.2. Drugs
The following drugs were used: creatine monohydrate, α-methyl-p-
tyrosine (AMPT), prazosin hydrochloride, (R)-(−)-phenylephrine hydro-
chloride, yohimbine hydrochloride, imipramine hydrochloride (Sigma
Chemical Co, USA), amitriptyline hydrochloride, reboxetine mesylate(Pﬁzer, Brazil). All drugswere dissolved in saline, except creatine, imipra-
mine, amitriptyline and reboxetine which were dissolved in distilled
water. All drugs were administered by intraperitoneal (i.p.) route, except
creatine, imipramine, amitriptyline and reboxetine which were adminis-
tered by oral route (p.o.) by gavage and creatine and phenylephrine that
was administered by intracerebroventricular (i.c.v.) route. All drugs,
except those administered centrally, were administered in a constant vol-
ume of 10 ml/kg body weight.
2.3. I.c.v. administration
I.c.v. administrationwas performed using amicrosyringe (25 μl, Ham-
ilton) connected to a 26-gauge stainless-steel needle that was inserted
perpendicularly 2 mmdeep through the skull according to the procedure
originally described by Laursen and Belknap (1986), which wasmodiﬁed
from the method of Haley and McCormick (1957). Brieﬂy, the animals
were anesthetized with ether and then gently restrained by hand for
i.c.v. injections. The sterilization of the injection site was carried out
using gauze embedded in 70% ethanol. Under light anesthesia (i.e. just
that necessary for loss of the postural reﬂex), the needlewas inserted uni-
laterally 1 mm to themidline point equidistant from each eye, at an equal
distance between the eyes and the ears and perpendicular to the plane of
the skull. A volume of 5 μl of sterile saline containing the drugs was
injected directly into the lateral ventricle, at the following coordinates
from bregma taken from the atlas of Franklin and Paxinos (1997):
anterioposterior (AP)=−0.1 mm;mediolateral (ML)=1 mm; and dor-
soventral (DV)=−3 mm.Mice exhibited normal behavior within 1 min
after injection. After completion of the experiments, all animals were
decapitated and their brains were examined freshly.
It is possible to check the site of the i.c.v. injections by visual inspec-
tion of the dissected brain. This is a standard procedure commonly
performed to determine the accuracy of the injection technique. Results
from mice presenting misplacement of the injection site or any sign of
cerebral hemorrhage were excluded from the statistical analysis (over-
all less than 5% of the total animals used).
2.4. Experimental design
2.4.1. Effect of i.c.v. administration of creatine in the TST or open-ﬁeld test
In a ﬁrst set of experiments, mice were administered with creatine
at doses of 0.01–1 μg/site, 15 min before the TST or open-ﬁeld test in
order to investigate its central effect.
2.4.2. Effect of administration of antidepressants in the TST or open-ﬁeld
test
Furthermore, mice were injected with the tricyclic antidepressants
imipramine and amitriptyline and the selective noradrenaline reuptake
inhibitor reboxetine (orally) at doses: 0.1–1, 1–10, and 2–20, respective-
ly, 60 min before the TST or open-ﬁeld test in order to establish effective
and subeffective doses of these antidepressants for subsequent studies.
2.4.3. Effect of AMPT administration on the creatine-induced reduction in
the immobility time in the TST and in the number of crossings in the
open-ﬁeld test
To test the hypothesis that the antidepressant-like effect of creatine is
mediated through an interactionwith the noradrenergic system, animals
were pretreated with AMPT (100 mg/kg, an inhibitor of the enzyme ty-
rosine hydroxylase) 4 h before the administration of creatine (1 mg/kg,
p.o.). This dose was previously established by our group to produce an
antidepressant-like effect in the TST, without altering locomotor activity
of mice (Cunha et al., 2012). As a positive control, α-methyl-p-tyrosine
(100 mg/kg, i.p.) was administered 4 h before the treatment of mice
with reboxetine (20 mg/kg, p.o.). A further 60 min elapsed between
reboxetine administration and the behavioral tests (TST or open-ﬁeld
test) (Fig. 1A).
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Fig. 1. Effect of creatine on AMPT-treated mice. Timeline of experimental protocol of administrations and behavioral tests (Panel A). Effect of pretreatment of mice with AMPT
(100 mg/kg, i.p., a tyrosine hydroxylase inhibitor) and treatment with creatine (1 mg/kg, p.o.) or reboxetine (20 mg/kg, p.o.) on the immobility time in the TST (Panels B and C,
respectively) and on the number of crossings in the open-ﬁeld test (Panels D and E, respectively). Each column represents the mean+S.E.M. **Pb0.01 compared with the
vehicle-treated control; ##Pb0.01 as compared with the same group pretreated with vehicle (two-way ANOVA followed by Newman–Keuls post-hoc test).
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open-ﬁeld test
Also, mice were injected by i.c.v. route with phenylephrine (an
α1-adrenoceptor agonist) at the dose range of 0.4–40 μg/site
15 min before the TST or open-ﬁeld test in order to establish effec-
tive and subeffective doses of these α1-adrenoceptor agonists for
subsequent studies.
2.4.5. Effect of the pretreatment with prazosin on the antidepressant-like
effect of creatine in the TST and in the number of crossings in the open-
ﬁeld test
In order to investigate the involvement of α1-adrenoceptors in
the anti-immobility effect of creatine in the TST, mice were
pretreated with prazosin (1 mg/kg, i.p., an α1-adrenoceptor antago-
nist), 30 min before the administration of creatine (1 mg/kg, p.o.).
Animals were submitted to the TST 60 min later (Fig. 2A). As a posi-
tive control, mice were pretreated with vehicle (control group) or
prazosin (1 mg/kg, i.p.) and 30 min later they received vehicle or
phenylephrine (40 μg/site, i.c.v., an α1-adrenoceptor agonist). After
15 min of the last treatment, the TST or open-ﬁeld test was carried
out (Fig. 2B).2.4.6. Interaction of creatine with α1-adrenoceptor agonist phenylephrine
in the TST and open-ﬁeld test
Alternatively, animals were pretreated with a dose of creatine
(0.01 mg/kg, p.o.) that was previously shown to be subeffective in the
TST (Cunha et al., 2012) 45 min before the administration of subeffective
doses of phenylephrine (0.4 μg/site, i.c.v.). After 15 min following the
administrations, the TST or open-ﬁeld test was carried out (Fig. 3A).
2.4.7. Effect of the pretreatment with yohimbine on the creatine-induced
reduction in the immobility time in the TST and in the number of crossings
in the open-ﬁeld test
In an attempt to investigate the participation of α2-adrenoceptors
in the antidepressant-like effect of creatine in the TST, yohimbine
(1 mg/kg, i.p., an α2-adrenoceptor antagonist) or vehicle was admin-
istered 30 min before creatine (1 mg/kg, p.o.). The TST was carried
out 60 min later (Fig. 4A).
2.4.8. Interaction of creatine with conventional antidepressants in the
TST and open-ﬁeld test
In order to investigate the potential synergistic effect of a
subeffective dose of creatine (0.01 mg/kg) with subeffective doses
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Fig. 2. Involvement of α1-adrenoceptors activation on the antidepressant-like effect of creatine in the TST. Timeline of reversal protocol of the antidepressant-like effect of creatine
or phenylephrine by prazosin (Panels A and B, respectively). Effect of pretreatment of mice with prazosin (1 mg/kg, i.p., an α1-adrenoceptor antagonist) on the anti-immobility
effect of creatine (1 mg/kg, p.o.) or phenylephrine (40 μg/site, i.c.v., an α1-adrenoceptor agonist) in the TST (Panels C and D, respectively) and on the number of crossings in
the open-ﬁeld test (Panels E and F, respectively). Each column represents the mean+S.E.M. *Pb0.05 compared with the vehicle-treated control; ##Pb0.01 as compared with
the same group pretreated with vehicle (two-way ANOVA followed by Newman–Keuls post-hoc test).
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p.o.) and reboxetine (2 mg/kg, p.o.) in the TST or open-ﬁeld test, creatine
or vehicle administration was followed by another immediate adminis-
tration of the antidepressant drug or vehicle 60 min before the TST or
open-ﬁeld test (Fig. 5A).2.4.9. Effect of prazosin administration on the antidepressant-like effect
induced by the combination of sub-effective doses of creatine and
reboxetine in the TST and in the number of crossings in the open-ﬁeld
test
In another experiment, mice were pretreated with prazosin
(1 mg/kg, i.p.) or vehicle 30 min before the co-administration of crea-
tine (0.01 mg/kg, p.o.) with reboxetine (2 mg/kg, p.o.). Animals were
submitted to the TST 60 min later (Fig. 6A).
The doses of drugs (tyrosine hydroxylase inhibitor AMPT, noradren-
ergic receptor antagonists and agonists and amitriptyline, imipramine
and reboxetine) used were selected on the basis of literature data and
on previous results from our laboratory (Binfaré et al., 2009; Capra et
al., 2010; Jesse et al., 2010; Kaster et al., 2007; Machado et al., 2007,
2009; O'Leary et al., 2007).2.5. Behavioral tests
2.5.1. Tail suspension test (TST)
The TST has become one of the most widely used models for
assessing antidepressant-like activity in mice. The test is based on the
fact that animals subjected to the short-term inescapable stress of
being suspended by their tail, will develop an immobile posture. The
total duration of immobility induced by tail suspension was measured
according to the method described by Steru et al. (1985). Brieﬂy, mice
were acoustically and visually isolated and suspended 50 cm above
the ﬂoor by adhesive tape placed approximately 1 cm from the tip of
the tail. Immobility time was recorded during a 6 min period. Mice
were considered immobile only when they hung passively and
completelymotionless. The immobility timewas recorded by observers
blind to the drug treatment (Binfaré et al., 2009; Cunha et al., 2008;
Machado et al., 2009).
2.5.2. Open-ﬁeld test
To assess the possible effects of drugs on locomotor activity, mice
were evaluated in the open-ﬁeld paradigm as previously described
(Machado et al., 2009). Mice were individually placed in a wooden
AB
C
Fig. 3. Synergistic antidepressant-like effect of combination between subeffective
doses of creatine and phenylephrine in the TST. Timeline of experimental protocol of
administrations and behavioral tests (Panel A). Effect of the treatment with
subeffective doses of creatine (0.01 mg/kg, p.o.) in combination with phenylephrine
(0.4 μg/site, i.c.v., an α1-adrenoceptor agonist) on the immobility time in the TST
(Panel B) and on the number of crossings in the open-ﬁeld test (Panel C). Each column
represents the mean+S.E.M. **Pb0.01 compared with the vehicle-treated control
(two-way ANOVA followed by Newman–Keuls post-hoc test).
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The number of rectangles crossed by the animal with its four paws
(crossing) and rising of the front paws (rearing) were registered dur-
ing a period of 6 min. The number of crossings and rearings was con-
sidered as indicative of locomotor activity and exploratory behavior,
respectively. The behavior was recorded by observers blind to the
drug treatment. The ﬂoor of the open-ﬁeld apparatus was cleaned
with 10% ethanol between tests.
2.6. Statistical analysis
Comparisons between experimental and control groups were
performed by one-way (dose–response curve of creatine or antidepres-
sants or phenylephrine in the TST and open-ﬁeld test inmice), two-way(experiments dealing with the involvement of the noradrenergic sys-
tem in the effect of creatine in the TST or open-ﬁeld test in mice) or
three-way (experiments that aimed to analyze the involvement of the
α1-adrenoceptor in the effect of combined administration of creatine
and reboxetine in the TST or open-ﬁeld test) analysis of variance
(ANOVA) followed by Newman–Keuls test when the F valuewas signif-
icant, as indicated on captions. A value of Pb0.05 was considered to be
signiﬁcant.
3. Results
3.1. Effect of the acute intracerebroventricular treatment with creatine
on the immobility time in the TST and on the number of crossings in
the open-ﬁeld test
Creatine administered at dose of 1 μg/site, but not at 0.01 and
0.1 μg/site, i.c.v., reduced the immobility time in TST in mice
(F(3,25)=5.16; Pb0.01; Table 1). Moreover, the one-way ANOVA
revealed that the administration of creatine by i.c.v. route did not
alter the number of crossings in the open-ﬁeld test in mice (P>0.05).
3.2. Effect of acute treatment with amitriptyline, imipramine and reboxetine
on the immobility time in the TST and on the number of crossings in the
open-ﬁeld test
The amitriptyline (1–10 mg/kg, a tricyclic antidepressant) admin-
istration by p.o. route at dose of 10 mg/kg reduced the immobility
time in TST in mice (F(2,19)=5.42; Pb0.05; Table 2). Imipramine
(1 mg/kg, p.o., tricyclic antidepressant) reduced the immobility time
in the TST (F(2,24)=17.38; Pb0.01; Table 2). Moreover, reboxetine
(selective noradrenaline reuptake inhibitor) administration by p.o.
route at dose of 20 mg/kg reduced the immobility time in TST in
mice (F(2,21)=73.49; Pb0.01). Furthermore, amitriptyline adminis-
tration at doses of 1–10 mg/kg, p.o., imipramine (0.1–1 mg/kg, p.o.)
and reboxetine (2–20 mg/kg, p.o.) were tested in the open-ﬁeld test
in mice (Table 2). The one-way ANOVA revealed that the administra-
tion of amitriptyline or imipramine by p.o. route did not alter the
number of crossings in the open-ﬁeld test in mice (Table 2).
Moreover, the one-way ANOVA revealed that the administration of
reboxetine by p.o. route (2–20 mg/kg) decrease the number of cross-
ings in the open-ﬁeld test (F(2,21)=4.92; Pb0.05).
3.3. Investigation of the pretreatment with AMPT on the effect of creatine
and reboxetine in the TST and open-ﬁeld test
The results depicted in Fig. 1B show that the anti-immobility effect
of creatine (1 mg/kg, p.o.) was prevented by pretreatment of mice
with the tyrosine hydroxylase inhibitor AMPT (100 mg/kg, i.p.) in the
TST. A two-way ANOVA showed signiﬁcant differences for AMPT treat-
ment (F(1,27)=29.17; Pb0.01), creatine treatment (F(1,27)=19.44;
Pb0.01), and AMPT×creatine treatment interaction (F(1,27)=4.52;
Pb0.05). The number of crossings in open-ﬁeld test was not altered
by AMPT and creatine treatments (Fig. 1D). A two-way ANOVA showed
signiﬁcant differences for creatine treatment (F(1,29)=16.81; Pb0.01),
but not for AMPT treatment and AMPT×creatine interaction.
The results depicted in Fig. 1C show that the anti-immobility effect of
reboxetine (20 mg/kg, p.o.)was prevented by pretreatment ofmicewith
the tyrosine hydroxylase inhibitor AMPT (100 mg/kg, i.p.) in the TST. A
two-way ANOVA showed signiﬁcant differences for AMPT treatment
(F(1,25)=28.83; Pb0.01), reboxetine treatment (F(1,25)=34.55;
Pb0.01), and AMPT×reboxetine treatment interaction (F(1,25)=5.31;
Pb0.05). Moreover, the effects of reboxetine and AMPT in the number
of crossings in the open-ﬁeld test are shown in Fig 1E. A two-way
ANOVA showed signiﬁcant differences for reboxetine treatment
(F(1,27)=25.28; Pb0.01), but not for AMPT treatment (F(1,27)=0.20;
P=0.63) and AMPT×reboxetine treatment interaction (F(1,27)=0.05;
AB C
Fig. 4. α2-adrenoceptors activation is not involved on the antidepressant-like effect of creatine in the TST. Timeline of reversal protocol of the antidepressant-like effect of creatine
by yohimbine (Panel A). Effect of pretreatment of mice with yohimbine (1 mg/kg, i.p., an α2-adrenoceptor antagonist) on the anti-immobility effect creatine (1 mg/kg, p.o.) in the
TST (Panel B) and on the number of crossings in the open-ﬁeld test (Panel C). Each column represents the mean+S.E.M. **Pb0.01, *Pb0.05 compared with the vehicle-treated con-
trol; ##Pb0.01 as compared with the same group pretreated with vehicle (two-way ANOVA followed by Newman–Keuls post-hoc test).
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AMPT alone, reduced the locomotor activity of mice.
3.4. Effect of acute treatment with phenylephrine on the immobility time
in the TST and on the number of crossings in the open-ﬁeld test
Phenylephrine (an α1-adrenoceptor agonist) administered by
i.c.v. route at the dose of 40 μg/site, but not at the doses of 4 and
0.4 μg/site, reduced the immobility time in the TST (Table 2). The
one-way ANOVA revealed a signiﬁcant main effect of phenylephrine
treatment (F(3,28)=5.45; Pb0.01). Furthermore, phenylephrine ad-
ministrations at doses of 0.4–40 μg/site, i.c.v. were tested in the
open-ﬁeld test in mice. The administration of phenylephrine did not
alter the number of crossings in the open-ﬁeld test (Table 2), as re-
vealed by one-way ANOVA (P>0.05).
3.5. Investigation of the pretreatment with prazosin on the effect of
creatine or phenylephrine in the TST and open-ﬁeld test
The results presented in Fig. 2C show that the anti-immobility effect
of creatine (1 mg/kg, p.o.) was prevented by pretreatment of mice with
the α1 adrenoceptor antagonist prazosin (1 mg/kg, i.p.) in the TST. A
two-way ANOVA showed signiﬁcant differences for prazosin treatment
(F(1,25)=9.87; Pb0.01), creatine treatment (F(1,27)=5.97; Pb0.05)
and prazosin×creatine treatment interaction (F(1,25)=5.92; Pb0.05).
The number of crossings in open-ﬁeld test was not altered by the
pretreatment with prazosin and creatine treatment (P>0.05, Fig. 2E).
Furthermore, the anti-immobility effect of phenylephrine (40 μg/site,
i.c.v.) was prevented by pretreatment of mice with prazosin (1 mg/kg,
i.p.) in the TST (Fig. 2D). A two-way ANOVA showed signiﬁcant
differences for prazosin treatment (F(1,28)=30.83; Pb0.01) and
prazosin×phenylephrine treatment interaction (F(1,28)=6.16;
Pb0.05), but not for phenylephrine treatment. Also, the number of
crossings in open-ﬁeld test was not altered by prazosin or phenyl-
ephrine alone or in combination (P>0.05, Fig. 2F).3.6. Effect of the interaction of subeffective doses of creatine and
phenylephrine on the immobility time in the TST and on the number of
crossings in the open-ﬁeld test
The α1-adrenoceptor agonist phenylephrine, administered at a
subeffective dose (0.4 μg/site, i.c.v.), exhibited a potent antidepressant-
like effect when combined with a subeffective dose of creatine
(0.01 mg/kg, p.o.) in the TST in mice as compared to the control or
either drug alone (Fig. 3B). A two-way ANOVA showed signiﬁcant differ-
ences for creatine treatment (F(1,29)=25.65; Pb0.01), phenylephrine
treatment (F(1,29)=55.37; Pb0.01), and creatine×phenylephrine
interaction (F(1,29)=6.97; Pb0.05). Moreover, the number of crossings
in open-ﬁeld test was not altered by the administration of creatine and
phenylephrine alone or in combination (Fig. 3C). A two-way ANOVA
shows no difference for creatine treatment, phenylephrine treatment
and creatine×phenylephrine interaction.
3.7. Effect of the pretreatment with yohimbine on the effect of creatine in
the TST and open-ﬁeld test
The result depicted in Fig. 4B shows that the anti-immobility effect
of creatine (1 mg/kg, p.o.) was not prevented by pretreatment of
mice with the α2-adrenoceptor antagonist yohimbine (1 mg/kg, i.p.)
in the TST. A two-way ANOVA showed signiﬁcant differences for cre-
atine treatment (F(1,24)=26.26; Pb0.01), but not for yohimbine
treatment and yohimbine×creatine treatment interaction. The num-
ber of crossings in open-ﬁeld test was not altered by the pretreatment
with yohimbine and creatine treatment (P>0.05, Fig. 4C).
3.8. Effect of the interaction of creatine with antidepressants on the
immobility time in the TST and on the number of crossings in the open-
ﬁeld test
The tricyclic antidepressant amitriptyline, administered at a sub-
effective dose (1 mg/kg, p.o.), exhibited a potent antidepressant-like
effect when combined with a subeffective dose of creatine (0.01 mg/kg,
AB C
D E
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Fig. 5. Synergystic antidepressant-like effect of combined administration between subeffective doses of creatine and antidepressants in the TST. Timeline of experimental protocol
of administrations and behavioral tests (Panel A). Effect of the treatment with subeffective doses of creatine (0.01 mg/kg, p.o.) in combination with amitriptyline (1 mg/kg, p.o.) or
imipramine (0.1 mg/kg, p.o.) or reboxetine (2 mg/kg, p.o.) on the immobility time in the TST (Panels B, D and E, respectively) and on the number of crossings in the open-ﬁeld test
(Panels C, E, and F, respectively). Each column represents the mean+S.E.M. **Pb0.01 compared with the vehicle-treated control (two-way ANOVA followed by Newman–Keuls
post-hoc test).
45M.P. Cunha et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 44 (2013) 39–50
AB
C
Fig. 6. Involvement ofα1-adrenoceptors activation on the antidepressant-like effect of com-
bined administrationof creatine and reboxetine in the TST. Timelineof experimental protocol
of administrations and behavioral tests (Panel A). Effect of pretreatment of mice with
prazosin (1 mg/kg, i.p., an α1-adrenoceptor antagonist) on the anti-immobility effect of the
co-treatment with subeffective doses of creatine (0.01 mg/kg, p.o.) in combination with
reboxetine (2 mg/kg, p.o.) in the TST (Panel A) and on the number of crossings in the
open-ﬁeld test (Panels B). Each column represents the mean+S.E.M. *Pb0.05, **Pb0.01
compared with the vehicle-treated control; ##Pb0.01 as compared with the same group
pretreated with vehicle (three-way ANOVA followed by Newman–Keuls post-hoc test).
Table 2
Effect of treatment with amitriptyline, imipramine, reboxetine and phenylephrine on
the immobility time in the TST and on the number of crossings in the open-ﬁeld test.
Compound Dose Immobility time (s) Number of crossings
Vehicle – 198.13±9.88 37.00±14.52
Amitriptyline 1 mg/kg, p.o. 164.71±26.31 31.86±9.49
Amitriptyline 10 mg/kg, p.o. 118.29±13.22⁎ 17.00±3.64
Vehicle – 221.78±8.40 34.82±10.68
Imipramine 0.1 mg/kg, p.o. 198.78±11.24 48.29±9.05
Imipramine 1 mg/kg, p.o. 147.56±7.22⁎⁎ 42.13±11.70
Vehicle – 193.78±6.96 47.22±12.88
Reboxetine 2 mg/kg, p.o. 182.14±11.43 13.00±6.68⁎
Reboxetine 20 mg/kg, p.o. 42.88±11.43⁎⁎ 11.75±3.79⁎
Vehicle – 229.00±12.27 24.83±9.58
Phenylephrine 0.4 μg/site, i.c.v. 186.38±18.89 27.88±8.52
Phenylephrine 4 μg/site, i.c.v. 157.57±21.49 39.63±7.14
Phenylephrine 40 μg/site, i.c.v. 134.14±28.68⁎ 22.29±8.86
Results are expressed as mean±S.E.M.
**Pb0.01, *Pb0.05 compared with the vehicle-treated control (one-way ANOVA
followed by Newman–Keuls post-hoc test).
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A two-way ANOVA showed signiﬁcant differences for amitriptyline
treatment (F(1,27)=12.35; Pb0.01), creatine treatment (F(1,27)=
6.25; Pb0.05), and amitriptyline×creatine interaction (F(1,27)=4.95;
Pb0.05). Moreover, the number of crossings in open-ﬁeld test was not al-
tered by the co-administration of creatine with amitriptyline (Fig. 5C),Table 1
Effect of treatment with creatine (0.01–1 μg/site, i.c.v.) on the immobility time in the
TST and in the number of crossings in the open-ﬁeld test.
Compound Dose Immobility time (s) Number of crossings
Vehicle – 192.18±20.06 63.2±10.07
Creatine 0.01 μg/site, i.c.v. 209.83±26.12 62.60±15.60
Creatine 0.1 μg/site, i.c.v. 137.17±16.57 72.60±7.05
Creatine 1 μg/site, i.c.v. 92.83±24.12⁎ 70.05±12.91
Results are expressed as mean±S.E.M.
⁎ Pb0.05 compared with the vehicle-treated control (one-way ANOVA followed by
Newman–Keuls post-hoc test).since only a main effect of creatine treatment was revealed by two-way
ANOVA (F(1,28)=4.52; Pb0.05).
Furthermore, the tricyclic antidepressant imipramine administered
at a subeffective dose (0.1 mg/kg, p.o.), exhibited antidepressant-like ef-
fect when combined with a subeffective dose of creatine (0.01 mg/kg,
p.o.) in the TST as compared to control or either drug alone (Fig. 5D). A
two-way ANOVA showed signiﬁcant differences for imipramine
treatment (F(1,22)=4.89; Pb0.05), creatine treatment (F(1,22)=
8.50; Pb0.01), and imipramine×creatine interaction (F(1,22)=
7.06; Pb0.05). Moreover, the number of crossings in open-ﬁeld test
was not altered by the co-administration of creatine with imipra-
mine (Fig. 5E).
Moreover, reboxetine administered at a subeffective dose (2 mg/kg,
p.o.), exhibited antidepressant-like effect when combined with a sub-
effective dose of creatine (0.01 mg/kg, p.o.) in the TST as compared
with the control group or either drug alone (Fig. 5F). A two-way
ANOVA showed signiﬁcant differences for reboxetine treatment
(F(1,26)=19.85; Pb0.01), creatine treatment (F(1,26)=11.68; Pb0.01)
and reboxetine×creatine interaction (F(1,26)=6.95; Pb0.05).Moreover,
reboxetine alone, but not in combinationwith creatine, reduced the loco-
motor activity ofmice (Fig. 5G). A two-wayANOVA showeddifference for
reboxetine treatment (F(1,27)=7.80; Pb0.01) and reboxetine×creatine
interaction (F(1,27)=4.65; Pb0.05), but not for creatine treatment.
3.9. Effect of pretreatment with prazosin on anti-immobility effect
induced by the combined administration of creatine and reboxetine in
the TST
The result depicted in Fig. 6B shows that the anti-immobility effect
produced by the combined administration of creatine (0.01 mg/kg, p.o.)
and reboxetine (2 mg/kg, p.o.) in the TSTwas prevented by pretreatment
of mice with the α1-adrenoceptor antagonist prazosin (1 mg/kg, i.p.). A
three-way ANOVA showed signiﬁcant differences for reboxetine treat-
ment (F(1,51)=8.63; Pb0.01), creatine treatment (F(1,51)=15.86;
Pb0.01), prazosin treatment (F(1,51)=14.94; Pb0.01), reboxetine×
creatine interaction (F(1,51)=9.97; Pb0.01), reboxetine×prazosin
interaction (F(1,51)=10.94; Pb0.01), creatine×prazosin interaction
(F(1.51)=16.19; Pb0.01), prazosin×creatine×reboxetine interaction
(F(1,51)=4.20; Pb0.05).
The number of crossings in open-ﬁeld test was altered by treatment
with reboxetine alone, but not with creatine, prazosin or combined
administrations (Fig. 6C). A three-way ANOVA showed signiﬁcant differ-
ences for prazosin×creatine×reboxetine interaction (F(1,55)=9.05;
Pb0.01), but not for creatine treatment, reboxetine treatment, prazosin
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tion and reboxetine×creatine treatment interaction.
4. Discussion
The results presented herein indicate that creatine produces
antidepressant-like effect in TST dependent at least in part on the α1-
adrenoceptor activation. Interestingly, we also show that creatine pre-
sents adjunctive effect when associated with amitriptyline, imipramine
and reboxetine, antidepressants that inhibit noradrenaline transporter.
These ﬁndings contribute to the understanding of the mechanism
underlying the antidepressant-like effect of creatine and are in line
with the reported antidepressant effect of creatine shown in clinical
(Amital et al., 2006; Kondo et al., 2011, 2012; Roitman et al., 2007) and
preclinical studies (Allen et al., 2010, 2012; Cunha et al., 2012), further
reinforcing the notion that creatine exerts an important role in themod-
ulation of depression.
The antidepressant-like effect of creatine (p.o.) was observed
60 min after its administration by oral route. It is in line with the fact
that systemic administration of creatine in rodents elicits several central
effects such as antidepressant (Cunha et al., 2012), anticonvulsant
(Magni et al., 2007; Royes et al., 2006) and spatial learning enhance-
ment (Oliveira et al., 2008; Souza et al., 2012). Moreover, a single sys-
temic administration of creatine was reported to increase striatal
creatine and phosphocreatine content and creatine kinase in the brain
of rats (Rambo et al., in press; Royes et al., 2006). In line with this, we
show that creatine administered i.c.v. exerts antidepressant-like effect
in the TST.
Creatine levels have been shown to be disrupted in the hippocam-
pus of adult patients undergoing a ﬁrst affective episode (Blasi et al.,
2004) and to be signiﬁcantly lower in euthymic adult male bipolar
patients (Deicken et al., 2003). In addition, agents with reported antide-
pressant activity cause changes in brain levels of creatine-containing
compounds, as acetyl-L-carnitine that increased phosphocreatine
brain levels in geriatric depressed patients (Pettegrew et al., 2002)
and in healthy mice (Smeland et al., 2012). Accordingly, two open-
labeled studies found that creatine can signiﬁcantly improve depressive
mood (Amital et al., 2006; Roitman et al., 2007). Furthermore, eight
weeks of creatine augmentation decrease the depression score in ado-
lescents with antidepressant-resistant depression (Kondo et al., 2011).
Moreover, creatine produced antidepressant-like effect in TST and
forced swimming test (FST), two predictive tests of antidepressant
properties, in rodents (Allen et al., 2010, 2012; Cunha et al, 2012).
The TST is widely used to assess the antidepressant properties of
new drugs, as it is sensitive to all major classes of antidepressant
drugs, including tricyclics, selective noradrenaline reuptake inhibitors
and monoamine oxidase inhibitors (Steru et al., 1985) and is an
important tool to study neurobiological mechanisms involved in anti-
depressant responses. The basic concept of this test called “searching–
waiting strategy” can be explained by alteration between two kinds of
behaviors, agitation and immobility, whenmicewere placed in aversive
situations (Steru et al., 1985). The immobility in the TST represents a
failure of persistence in escape-directed behavior and effective antide-
pressant treatments decrease immobility time in the TST (Cryan et al.,
2005; Steru et al., 1985). “False” positive effects in this test do occur
with stimulants interventions due to the generalized increase in
motor activity, which is controlled for by use of an additional test for
ambulation. Amount of ambulation has usually been scored spatially
by the number of subdivisions entered in the open-ﬁeld test. The reduc-
tion in the immobility time elicited by creatine in the TST cannot be
attributable to a psychostimulant action of this compound. This conclu-
sion derives from the fact that in our study creatine administered either
by p.o. and i.c.v. routes at doses that produced a signiﬁcant decrease in
the immobility time (1 mg/kg, p.o. and 1 μg/site, i.c.v.) in the TST did
not alter the locomotor activity in open-ﬁeld test, as compared to con-
trol animals.In the 1960s, based on over a decade of accumulating data, a con-
sensus was forming that catecholamines, speciﬁcally noradrenaline,
play an important, possibly primary, role in the pathophysiology
and subsequent treatment of mood disorders (Brunello et al., 2002;
Bunney and Davis, 1965). Furthermore, antidepressant treatments with
selective noradrenaline reuptake inhibitors and with serotonergic-
speciﬁc agents cause decreased noradrenaline turnover (DeBellis et al.,
1993; Javaid et al., 1983; Potter et al., 1985). Recent studies have
reported the implication of noradrenaline as one of the important targets
in the action of antidepressant compounds (Cardoso et al., 2009; Kaster
et al., 2007; Machado et al., 2007, 2009). Furthermore, the treatment
with acetyl-L-carnitine, compound endowed with antidepressant-like
properties in the FST, increases the phosphocreatine and the phospho-
creatine/creatine ratio associated with increases in the levels of
noradrenaline in the cerebral cortex of mice (Di Cesare et al., 2011;
Pulvirenti et al., 1990; Smeland et al., 2012). In the present work,
the pretreatment of mice with AMPT was able to prevent the anti-
immobility effect of creatine in the TST, an effect similar to the observed
with the selective noradrenaline reuptake inhibitor reboxetine. These
results suggest that the effect of creatine in the TST may be dependent
on the bioavailability of noradrenaline in the synaptic cleft. The nor-
adrenaline depletion paradigm has been successfully used to investigate
the mechanism of action of antidepressants in preclinical and clinical
studies (Kaster et al., 2007; Machado et al., 2008; Miller et al., 1996a,b).
Studies reported the ability of selective inhibitor of the enzyme tyrosine
hydroxylase AMPT to reduce dopamine and noradrenaline levels (57%
and 53%, respectively) in mice, without affecting the levels of serotonin
(Mayorga et al., 2001). Furthermore, AMPT generated a relapse of
depression in depressed patients currently treated with a noradrenaline
reuptake inhibitor, but not with patients treatedwith selective serotonin
reuptake inhibitors (Bremner et al., 2003; Miller et al., 1996a,b). In addi-
tion, the acute administration of AMPT temporarily reversed the antide-
pressant response to desipramine, mazindol andmirtazapine in patients
(Delgado et al., 1993, 2002; Miller et al., 1996a,b). Moreover, our group
reported that the administration of AMPT at the same dose employed
in the present study reversed the antidepressant-like action of antide-
pressant compounds, such as lamotrigine and rutin, in the FST and TST
in mice, respectively (Kaster et al., 2007; Machado et al., 2008). We can-
not rule out the possibility that the effect of AMPT to abolish the
antidepressant-like property of creatine is due, at least in part, to a
decrease in dopamine levels, since a previous study fromour group dem-
onstrated that the antidepressant-like effect of creatine could bemediat-
ed by activation of the dopaminergic system (Cunha et al., 2012).
Basic studies on the effects of antidepressants on brain α1-
adrenoceptor indirectly support the notion of an impaired function of
α1-adrenoceptor in depression. Many authors have reported that treat-
ment with tricyclic antidepressants increases either density (Maj et al.,
1985; Vetulani et al., 1984), agonist afﬁnity (Maj et al., 2000; Menkes et
al., 1983), electrophysiological response (Menkes et al., 1980), or be-
havioral response mediated by α1-adrenoceptors (Maj et al.,
2000; Menkes et al., 1983). The present study suggests that the
antidepressant-like effect of creatine in the TST is dependent, at least
in part, on an activation of α1-adrenoceptor, since the pretreatment
of mice with prazosin (α1-adrenoceptor antagonist) signiﬁcantly
prevented the antidepressant-like effect evoked by creatine in the
TST. In line with this, prazosin prevented the antidepressant-like effect
of antidepressant compounds in the TST (Binfaré et al., 2009; Capra et
al., 2010; Machado et al., 2009). Besides that, the antidepressant-like ac-
tion of desipramine in the FSTwas prevented by the pretreatment ofmice
with prazosin (Danysz et al., 1986). Moreover, the α1-adrenoceptor ago-
nist phenylephrine produced an anti-immobility effect in the FST (Kitada
et al., 1983), in agreement with the present study that shows an
antidepressant-like effect produced by phenylephrine in the TST,
which was prevented by the pretreatment of mice with prazosin. In ad-
dition, the results presented herein indicate that creatine administered
at a subeffective dose exerts a synergistic anti-immobility effect in the
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reinforcing the assumption that creatine exerts an antidepressant-like
effect by directly or indirectly activating α1-adrenoceptors.
Our results also suggest that the effect of creatine in the TST is not
dependent on an interaction with the α2-adrenoceptor, considering
that the pretreatment of mice with yohimbine (α2-adrenoceptor
antagonist) did not prevent the antidepressant-like effect evoked by
creatine in the TST. Interestingly, the antidepressant-like action of
some compounds is not blocked by yohimbine (Machado et al.,
2009; Yi et al., 2011).
Taking into account that: (i) the adrenergic receptors may be
physiologically activated by dopamine (Zhang et al., 2004), (ii) the
α1-adrenoceptor is a afferent system of the dopaminergic neurons
(Lipinski et al., 1987), (iii) noradrenaline reuptake inhibitors can
increase the extracellular concentrations of dopamine in the prefrontal
cortex (Carboni et al., 1990; Tanda et al., 1994), (iv) the antidepressant-
like effect of creatine in TST involves dopaminergic activation (Cunha et
al., 2012), we cannot rule out the possibility that some of the actions of
creatine in the TST may be mediated by an interaction between dopami-
nergic and noradrenergic systems.
The noradrenaline transporters located in the plasma membrane
of noradrenergic neurons are responsible for the rapid reuptake of
neuronally released noradrenaline into presynaptic terminals. It is
therefore critically involved in the termination of noradrenergic neuro-
transmission regulating noradrenaline-mediated behavioral and physi-
ological effects, including mood regulation (Bönisch and Brüss, 2006).
The noradrenaline transporters are a target for antidepressants such
as amitriptyline, imipramine and reboxetine which are clinically used
for the treatment of depression (Haenisch and Bönisch, 2011). Imipra-
mine and amitriptyline are dual serotonin and noradrenaline reuptake
inhibitors (Carrodi and Fuxe, 1968; Richelson and Pfenning, 1984),
whereas reboxetine is a selective noradrenaline reuptake inhibitor
used in the treatment of depression (Hajós et al., 2004; Kasper et al.,
2000). In the present study, amitriptyline, imipramine and reboxetine
were effective in reducing the immobility time in the TST. TST is widely
used to assess the antidepressant properties of new antidepressant
interventions, as it is sensitive to all major classes of antidepressant
drugs, including tricyclics and selective noradrenaline reuptake inhibi-
tors (Caldarone et al., 2004; Cunha et al., 2008; O'Leary et al., 2007;
Steru et al., 1985). Interestingly, in the present study, reboxetine
decreased the ambulation of the animals in the open-ﬁeld test. Thus,
the antidepressant-like effect of reboxetine cannot be attributable to a
psychostimulant action of this compound, since reboxetine adminis-
tered by p.o. route at a dose that produced a signiﬁcant decrease in
the immobility time in the TST (20 mg/kg, p.o.) decreased the locomo-
tor activity in open-ﬁeld test.
The synergistic antidepressant-like effects of creatine with the tri-
cyclics amitriptyline and imipramine, and selective noradrenaline
reuptake inhibitor reboxetine were shown herein. The effect of the
combined administration of reboxetine and creatine in the TST is sim-
ilar to the reported synergistic effect elicited by the combined admin-
istration of reboxetine and metyrapone in the FST in rats (Rogóz,
2009). Moreover, lithium augmentation (the best validated augmen-
tation strategy) should also be considered as a treatment strategy in
case of nonresponse to speciﬁc noradrenergic antidepressant
reboxetine (Khazaal et al., 2005). Furthermore, creatine blocked the
reduction in the number of crossings induced by reboxetine adminis-
tration in the open-ﬁeld test. Noteworthy, we showed that the
enhancement of the anti-immobility action of reboxetine by creatine
in the TST was abolished by prazosin, further implicating the
α1-adrenoceptor activation in the effect of creatine in the TST.
We should take into account that the TST is a validated tool to screen
acute antidepressant-like effects of certain compounds, but it does not
measure depression (Cryan et al., 2005). Therefore, further studies are
necessary to investigate if the synergistic antidepressant-like effect
obtained with sub-effective doses of creatine and α1-adrenoceptoragonists in the TST translate to animal models of depression or the clin-
ical syndrome. Furthermore, further studies are needed to address if
chronic treatment with creatine replicate the data obtained with crea-
tine administered acutely.
5. Conclusions
In conclusion, our results provide convincing evidence that
antidepressant-like effect of creatine in TST is dependent on an acti-
vation of α1-adrenoceptors. A synergistic antidepressant-like effect
was observed when subeffective doses of creatine and antidepres-
sants that modulate the noradrenaline transporter were administered
to mice, suggesting that creatine may be investigated in the future as
an augmentation agent for the treatment of depression associated
with noradrenergic dysfunctions. Finally, we indicate that combined
administration of creatine with the selective noradrenaline transport-
er reboxetine at subeffective doses produced antidepressant-like
effect in TST mediated by α1-adrenoceptor activation. Collectively, the
present ﬁndings indicate that creatine might constitute a potential
and relevant alternative or adjunctive therapy for the management of
depression. However, the results obtained with the TST should be con-
sideredwith caution, and further studies with animalmodels of depres-
sion and clinical paradigms are welcome.
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